GeneArt, Boehringer Ingelheim Team on DNA-based Therapeutics | GenomeWeb
NEW YORK (GenomeWeb News) – Drug developer Boehringer Ingelheim and synthetic biology company GeneArt will collaborate to develop DNA-based pharmaceutical agents for clinical trials that both companies will market, GeneArt said today.
 
Under the agreement, GeneArt will use Boehringer Ingelheim’s technology to produce and purify plasmid DNA for use in research and for commercial purposes, and Boehringer Ingelheim will produce plasmids for the subsequent clinical trials and for sale globally.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.